Blood Test May Track Alzheimer’s Drug Response
Researchers from Korea University found that changes in the blood biomarker p‑tau217 can indicate how patients respond to the Alzheimer’s drug lecanemab. The biomarker drops quickly after treatment starts, and larger declines correlate with better cognitive outcomes. If confirmed, blood testing cou…
By Felo News Desk · Published
In a breakthrough that could reshape Alzheimer’s care, scientists at Korea University College of Medicine have shown that a simple blood test can reveal how patients are biologically responding to lecanemab, one of the first disease‑modifying drugs approved for early Alzheimer’s disease. The study, which followed 153 patients in real‑world clinical settings, found that levels of phosphorylated tau 217 (p‑tau217) in the bloodstream fell within three months of starting the medication. Patients whose p‑tau217 dropped the most also showed slower cognitive decline on the Clinical Dementia Rating Scale‑Sum of Boxes (CDR‑SB), a standard measure of functional impairment.
From Symptom Relief to Targeted Therapy
For decades, Alzheimer’s treatment offered only symptomatic relief, leaving doctors with few tools to gauge whether a therapy was actually altering the disease process. The approval of lecanemab, a monoclonal antibody that clears amyloid‑beta plaques from the brain, marked a turning point. Clinical trials demonstrated that lecanemab can modestly slow cognitive decline in people with early disease, but those trials also highlighted a gap: how to confirm that amyloid removal translates into meaningful clinical benefit for each patient.
Why p‑tau217 Matters
Tau proteins stabilize neurons, but in Alzheimer’s they become abnormally phosphorylated and aggregate into tangles that disrupt brain function. Among the many tau‑related biomarkers under investigation, p‑tau217 has emerged as a strong indicator of Alzheimer’s pathology. Blood concentrations of p‑tau217 correlate closely with brain changes seen on PET scans and can differentiate Alzheimer’s from other neurodegenerative disorders. Importantly, blood sampling is far less invasive, cheaper, and more widely available than PET imaging or cerebrospinal fluid analysis.
Real‑World Evidence of a Responsive Biomarker
The Korean study’s prospective design mirrors everyday clinical practice, unlike the tightly controlled environments of randomized trials. Researchers measured p‑tau217 levels at baseline and at subsequent visits, then compared the biomarker’s trajectory with cognitive assessments. Within three months of initiating lecanemab, patients exhibited a significant reduction in circulating p‑tau217. The speed of this response suggests that the drug’s biological activity is captured promptly by the blood test.
More compelling, the magnitude of the p‑tau217 decline predicted cognitive outcomes. Those with the largest drops in the biomarker experienced the slowest worsening on the CDR‑SB, indicating that the blood test reflects not just biochemical changes but also real‑world functional benefits. This link between biomarker dynamics and clinical trajectories is a critical step toward using p‑tau217 as a pharmacodynamic marker.
Heterogeneity in Treatment Response
Not all patients followed the same pattern. The study identified distinct response trajectories, underscoring that Alzheimer’s is a heterogeneous disease influenced by genetics, vascular health, disease stage, and other factors. Hypertension emerged as a factor associated with a weaker p‑tau217 response, hinting at the interplay between vascular risk and neurodegeneration. While the study was not designed to establish causality, the finding emphasizes the importance of managing cardiovascular risk in patients receiving Alzheimer’s therapies.
Implications for Clinical Practice
Currently, monitoring the biological impact of anti‑amyloid therapies relies heavily on PET imaging, which is expensive, requires specialized equipment, and is not universally available. If future research confirms these findings, clinicians could rely on serial blood tests to track treatment response, dramatically reducing dependence on costly imaging. This shift would align with precision medicine’s goal of using minimally invasive biomarkers to tailor care and could expand access to monitoring in regions lacking advanced imaging infrastructure.
However, the authors caution that larger, longer‑term studies are needed before p‑tau217 can be adopted as a routine clinical tool. Key questions remain: How do biomarker levels evolve over extended treatment periods? What thresholds predict meaningful clinical benefit? How should p‑tau217 be interpreted alongside other emerging biomarkers? Addressing these questions will be essential for integrating the test into standard practice.
What’s Next?
Ongoing research will explore whether p‑tau217 can guide treatment decisions, such as determining whether to continue, adjust, or discontinue lecanemab. Additionally, investigators are examining the biomarker’s performance in diverse populations and in combination with other blood markers. As the field moves toward more personalized approaches, blood‑based biomarkers like p‑tau217 could become central to both diagnosis and therapeutic monitoring.
In sum, this study provides a promising glimpse into a future where a simple blood draw could inform clinicians about the effectiveness of Alzheimer’s treatments, potentially reducing the need for expensive brain scans and enabling more timely, individualized care.
Key facts
- Blood p‑tau217 levels fall within three months of lecanemab treatment.
- Greater biomarker reductions predict better cognitive trajectories.
- Response patterns differ among patients; hypertension weakens the response.
- Blood testing could replace expensive PET scans for monitoring.
- More research is needed to confirm thresholds and long‑term effects.
Why it matters
By providing a non‑invasive, cost‑effective way to monitor drug response, p‑tau217 testing could make disease‑modifying therapies more accessible and personalized, potentially improving outcomes for millions with Alzheimer’s.
Frequently asked questions
What is p‑tau217?
p‑tau217 is a phosphorylated form of the tau protein that accumulates in the brain during Alzheimer’s disease and can be measured in the blood.
How does lecanemab work?
Lecanemab is a monoclonal antibody that targets amyloid‑beta plaques, helping to clear them from the brain.
Can p‑tau217 replace PET scans?
While promising, p‑tau217 testing is not yet a full replacement for PET imaging; further studies are needed to validate its use in clinical practice.
Sources
- [1] digitaljournal.com — originally reported as “Blood biomarker offers window into Alzheimer’s drug response”
